GOLD Treatment Guidelines and Evolving Therapeutic Approaches

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.

Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.

The guideline chair answers key questions on new ferritin cutoffs, symptoms without anemia, inflammation, and lab reporting.

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.